title: Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapy.
abstract: Restriction of the T cell receptor repertoire suggesting ongoing specific immune mechanisms has recently been described in melanoma tissue by several groups of investigators. The functional relevance for immunotherapy of melanoma, however, has not been established. We studied the T cell receptor repertoire in two melanoma metastases of a patient with a mixed response to immunotherapy. Expression of T cell receptor V beta regions was determined by subgroup-specific semiquantitative RNA polymerase chain reaction (PCR). In the regressing skin lesion a restricted expression of the T cell receptor repertoire and overexpression of three V beta subgroup genes was found; no restriction was present in the simultaneously progressing skin lesion of the same patient, compared with peripheral blood lymphocytes. Comparison of T cell receptor V beta gene expression in two metastatic lesions of a patient with simultaneously growing skin metastases, who did not receive immunotherapy, revealed only minor differences. These observations show for the first time an association between restricted T cell receptor repertoire and responsiveness of melanoma to immunotherapy and suggest a role of T cells using the overexpressed V beta genes for the cytokine-induced tumour regression.
authors.affiliation: Department of Internal Medicine V, University of Heidelberg, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Möhler
authors.forename: M
authors.initials: M
authors.lastname: Willhauck
authors.forename: C
authors.initials: C
authors.lastname: Scheibenbogen
authors.forename: M
authors.initials: M
authors.lastname: Pawlita
authors.forename: H
authors.initials: H
authors.lastname: Bludau
authors.forename: P
authors.initials: P
authors.lastname: Brossart
authors.forename: W
authors.initials: W
authors.lastname: Hunstein
authors.forename: U
authors.initials: U
authors.lastname: Keilholz
mesh_terms: D004273:DNA, Neoplasm / Q000097:blood; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008545:Melanoma / Q000276:immunology* / Q000556:secondary / Q000628:therapy; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics* / Q000276:immunology; D012878:Skin Neoplasms / Q000276:immunology* / Q000556:secondary / Q000628:therapy
chemical_list: D004273:DNA, Neoplasm; D016898:Interferon-alpha; D007376:Interleukin-2; D016693:Receptors, Antigen, T-Cell, alpha-beta